Icosabutate, a novel structurally engineered fatty-acid, exhibits potent anti-inflammatory and anti-fibrotic effects in a dietary mouse model resembling progressive human NASH

A liver-targeted structurally engineered fatty acid, icosabutate, potently reduces hepatic pro-fibrotic gene expression and improves glycemic control in an obese diet-induced mouse model of NASH

Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.

Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.

A structurally engineered fatty acid, icosabutate, displays optimised absorption, distribution and metabolism properties for targeting hepatic inflammation and normalises elevated liver enzymes in dyslipidemic patients.

“We believe icosabutate has the potential to impact the lives of millions of NASH patients globally”

Rob de Ree

Chief Executive Officer, NorthSea Therapeutics

Voor meer informatie:

+31 (0) 35 760 65 05